Abbott Raises $20 Billion in Debt to Fund $49 Billion Exact Sciences Deal

Abbott Laboratories (NYSE: ABT) has successfully raised $20 billion through a multi-tranche bond offering, marking one of the largest corporate debt issuances of 2026, according to an SEC filing on March 9. The healthcare giant is using the proceeds to finance its $49 billion acquisition of Exact Sciences Corporation, the maker of Cologuard colorectal cancer screening tests.

The Deal

The $20 billion offering consists of eight separate tranches with maturities ranging from 2029 to 2066:

• $1 billion in Floating Rate Notes due 2029
• $2.25 billion in 3.700% Notes due 2029
• $2.5 billion in 4.000% Notes due 2031
• $2.75 billion in 4.300% Notes due 2033
• $3.75 billion in 4.650% Notes due 2036
• $2 billion in 4.750% Notes due 2038
• $3.75 billion in 5.500% Notes due 2056
• $2 billion in 5.600% Notes due 2066

The bonds carry a special mandatory redemption provision tied to the Exact Sciences acquisition. If the deal doesn't close by February 17, 2027 (or any agreed extension), Abbott must redeem all outstanding notes at 101% of principal plus accrued interest. This provision protects bondholders from holding Abbott debt if the transformative acquisition falls through.

The offering was led by Morgan Stanley, Barclays Capital, Bank of America Securities, and J.P. Morgan Securities. Interest rates range from 3.7% on the shortest-dated fixed-rate notes to 5.6% on the 40-year bonds, reflecting current market conditions and Abbott's strong investment-grade credit rating.

Strategic Rationale

The massive debt raise underscores Abbott's commitment to the Exact Sciences acquisition, originally announced in November 2025. The combined company will create a diagnostics powerhouse, adding Exact Sciences' innovative cancer screening technologies to Abbott's existing portfolio of medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

Exact Sciences brings critical capabilities in molecular diagnostics and cancer detection, particularly its flagship Cologuard test, which has revolutionized at-home colorectal cancer screening. The acquisition aligns with Abbott's strategy to expand its presence in high-growth diagnostic markets and leverage its global commercial infrastructure to accelerate Exact Sciences' international expansion.

The debt financing structure demonstrates Abbott's confidence in its ability to integrate Exact Sciences and generate sufficient cash flows to service the new debt. By spreading maturities across multiple decades, Abbott maintains financial flexibility while avoiding a concentrated refinancing risk. The longest-dated bonds extending to 2066 suggest management's view of the acquisition as a multi-generational investment in the company's future.

What to Watch

Several key factors will determine the success of this financing and the broader transaction:

Regulatory Timeline: The February 2027 deadline provides nearly a year for regulatory approvals, but given the size of the deal, antitrust scrutiny from the Federal Trade Commission and international regulators remains a key risk. Any required divestitures could impact the deal's strategic value.

Integration Costs: Beyond the $20 billion raised, Abbott noted it will use additional cash and borrowings to repay Exact Sciences' existing debt and cover transaction fees. The total financing package could exceed $25 billion when including refinancing and integration expenses.

Leverage Metrics: Adding $20 billion in debt will significantly increase Abbott's leverage ratios. Credit rating agencies will closely monitor the company's ability to deleverage post-acquisition through operational improvements and potential asset sales.

Market Conditions: With interest rates ranging from 3.7% to 5.6%, Abbott locked in financing before potential further rate increases. However, the floating rate tranche exposes the company to interest rate risk if rates rise before the 2029 maturity.

Synergy Realization: Abbott will need to demonstrate clear progress on cost and revenue synergies to justify the substantial premium paid for Exact Sciences and the increased debt burden. Investors will look for detailed integration plans and synergy targets in upcoming earnings calls.

The successful bond offering removes financing uncertainty from the Exact Sciences acquisition, but execution risk remains. Abbott's ability to integrate Exact Sciences while maintaining its own operational momentum will be crucial for creating shareholder value from this transformative transaction.